Liang Cheng: Comprehensive resource on AI applications for prostate cancer management
Liang Cheng, Director of Anatomic Pathology and Molecular Pathology at Warren Alpert Medical School of Brown University, shared a post on X by Paulo Bergerot, MD, post-doctoral fellow at City of Hope, adding:
“It is such a great honor to work with Irbaz, Arsalan, Stephanie, and Zhiqun to create this comprehensive resource on AI applications for prostate cancer management. This is a work in progress, and we will keep you posted on our next project.”
Quoting Paulo Bergerot’s post:
“Our very long flight back home from ANZUP24 Gold Coast to Brasilia means there’s time to catch up on some reading. Many thanks to ASCO Publications emails with outstanding articles from the ASCO Educational Book.
1. Strategies to reduce AEs of ADT in prostate cancer care.
- behavioural
- pharmacologic and
- ADT-sparing alternatives for hormone-sensitive and castration-resistant prostate cancer.
Struan Gray, LisaGudenkauf
2. Optimizing treatment for Your patient with Urothelial Cancer.
Potential biomarkers to guide management of bladder cancer
The changing landscape of frontline treatment for patients with mUC.
Gregory Hemenway, Matt Galsky, Pooja Ghatalia
“Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient”
3. How AI technologies are poised to advance Prostate Cancer cancer care from early interception to end-of-life treatment, from evidence generation to clinical practice guideline development.
Irbaz Riaz, Liang Cheng
4. Recent developments of functional imaging and immunotherapy strategies in renal cell carcinoma and the evidence supporting treatment sequencing.
Yu-Wei Chen, Muhammad Ali
5. New insights into RCC Kidney Cancer of variant histology are leading to therapeutic advances.
The paper discusses evolving treatment for papRCC and RCC with sarcomatoid differentiation.
Nick Salgia, Zeynep Zengin, Sumanta Pal, Nazli Dizman
6. Advancing prostate cancer: precision medicine, biomarker innovations, equitable access.
The paper discusses genetics, molecular imaging & the need for equity in treatment approaches.
Sarah Fenton, Delphine Chen, David Vander Weeler
7. Updates on Recent adv in managing non-urothelial bladder cancer subtypes, often with worse prognosis than UC
Treatments are typically extrapolated from UC.
Evangelia Vlachou, Jean Hoffman-Censits
“Current Advances in the Management of Nonurothelial Subtypes of Bladder Cancer”
8. Integrating palliative care into genitourinary cancer management is crucial.
This review the key challenges and importance of pall interv. and comprehensive care.
Eva Masel, Claudia Wenzel
“Integrating Palliative Care Into the Management of Genitourinary Malignancies”
Sources: Liang Cheng/X and Paulo Bergerot/X